help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uchiba, M.
Right arrow Articles by Takatsuki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uchiba, M.
Right arrow Articles by Takatsuki, K.

Am. J. Respir. Crit. Care Med., Vol 155, No. 2, 02 1997, 711-718.

Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats

M Uchiba, K Okajima, K Murakami, H Okabe and K Takatsuki
Department of Medicine, Kumamoto University Medical School, Japan.

Nafamostat mesilate (NM) is a synthetic protease inhibitor that is capable of inhibiting the various coagulation factors such as factor VIIa and thrombin. To determine whether NM may also be useful in treating adult respiratory distress syndrome (ARDS) related in sepsis, we investigated the effect of NM on lipopolysaccharide (LPS)-induced pulmonary vascular injury in rats. The intraperitoneal administration of NM prevented the pulmonary vascular injury and coagulation abnormalities induced by LPS. DEGR-factor VIIa, a selective inhibitor of factor VIIa, prevented the coagulation abnormalities, but not the pulmonary vascular injury, induced by LPS. NM did not reduce LPS- induced increase in pulmonary accumulation of leukocytes. NM did not inhibit the increase in the plasma concentration of tumor necrosis factor-alpha (TNF-alpha) observed after administration of LPS. NM did not inhibit the function of activated neutrophils in vitro. Plasma values of total serum hemolytic complement (CH50) were markedly decreased after the administration of LPS. NM inhibited the LPS-induced decrease in plasma CH50 values. Findings suggest that NM may reduce the pulmonary vascular injury as well as the coagulation abnormalities induced by LPS. The former effect may be independent of the anticoagulant effect but dependent on the inhibitory effect of the activation of the complement system in rats administered LPS.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Molor-Erdene, K. Okajima, H. Isobe, M. Uchiba, N. Harada, and H. Okabe
Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-{alpha} production through inhibition of Egr-1 expression
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1265 - H1271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. Okajima, N. Harada, M. Uchiba, and M. Mori
Neutrophil elastase contributes to the development of ischemia-reperfusion-induced liver injury by decreasing endothelial production of prostacyclin in rats
Am J Physiol Gastrointest Liver Physiol, December 1, 2004; 287(6): G1116 - G1123.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, A. Tachibana, Y. Soeno, K. Asahina, H. Hino, et al.
Near Completely Humanized Liver in Mice Shows Human-Type Metabolic Responses to Drugs
Am. J. Pathol., September 1, 2004; 165(3): 901 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. G. Laffey, D. Honan, N. Hopkins, J.-M. Hyvelin, J. F. Boylan, and P. McLoughlin
Hypercapnic Acidosis Attenuates Endotoxin-induced Acute Lung Injury
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 46 - 56.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Yuksel, K. Okajima, M. Uchiba, and H. Okabe
Gabexate Mesilate, a Synthetic Protease Inhibitor, Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-alpha Production by Inhibiting Activation of Both Nuclear Factor-kappa B and Activator Protein-1 in Human Monocytes
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 298 - 305.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. ENKHBAATAR, K. OKAJIMA, K. MURAKAMI, M. UCHIBA, H. OKABE, K. OKABE, and Y. YAMAGUCHI
Recombinant Tissue Factor Pathway Inhibitor Reduces Lipopolysaccharide-Induced Pulmonary Vascular Injury by Inhibiting Leukocyte Activation
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1752 - 1759.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. MURAKAMI, K. OKAJIMA, and M. UCHIBA
The Prevention of Lipopolysaccharide-induced Pulmonary Vascular Injury by Pretreatment with Cepharanthine in Rats
Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 57 - 63.
[Abstract] [Full Text]

Home page
 Infect. Immun.Home page
E. Isogai, H. Isogai, K. Kimura, S. Hayashi, T. Kubota, N. Fujii, and K. Takeshi
Role of Tumor Necrosis Factor Alpha in Gnotobiotic Mice Infected with an Escherichia coli O157:H7 Strain
Infect. Immun., January 1, 1998; 66(1): 197 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Uchiba, K. Okajima, K. Murakami, M. Johno, M. Mohri, H. Okabe, and K. Takatsuki
rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation
Am J Physiol Lung Cell Mol Physiol, October 1, 1997; 273(4): L889 - L894.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society